• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鸟氨酸转氨甲酰酶缺乏症的生化与分子谱

The biochemical and molecular spectrum of ornithine transcarbamylase deficiency.

作者信息

Tuchman M, Morizono H, Rajagopal B S, Plante R J, Allewell N M

机构信息

Department of Pediatrics, Medical School, University of Minnesota, St. Paul, USA.

出版信息

J Inherit Metab Dis. 1998;21 Suppl 1:40-58. doi: 10.1023/a:1005353407220.

DOI:10.1023/a:1005353407220
PMID:9686344
Abstract

Ornithine transcarbamylase (OTCase) deficiency, the most common inherited urea cycle disorder, is transmitted as an X-linked trait. The clinical phenotype in affected males as well as heterozygous females shows a spectrum of severity ranging from neonatal hyperammonaemic coma to asymptomatic adults. The ornithine transcarbamylase enzyme is a trimer with three active sites per holoenzyme molecule, each of which is composed of an interdomain region of one polypeptide and a polar domain of the adjacent polypeptide. The OTC gene is located on the short arm of the X-chromosome and one of the two alleles undergoes inactivation in female cells. Approximately 140 mutations have been found in families affected with OTCase deficiency, most having their own 'private' mutation. Large deletions of one exon or more are seen in approximately 7% of patients, small deletions or insertions are seen in about 9%, and the remaining mutations are single base substitutions. Approximately 15% of mutations affect RNA splicing sites. The recurrent mutations are distributed equally among CpG dinucleotide hot spots. Generally, mutations causing neonatal disease affect amino acid residues that are 'buried' in the interior of the enzyme, especially around the active site, while those associated with late onset and milder phenotypes tend to be located on the surface of the protein. Very few mutations have been found in the sequence of the leader peptide, proportionally much fewer than in the sequence of the mature enzyme. Only few of the mutations have been expressed in bacteria or mammalian cells for the study of their deleterious mechanisms. Examples of expressed mutations include R277W and R277Q associated with late-onset disease, which markedly increase the Km for ornithine, shift the pH optimum to more alkaline and decrease the thermal stability of the purified mutant enzyme. R141Q (neonatal disease) disrupts the active site, whereas the purified R40H mutant has normal catalytic function and this mutation is likely to affect posttranslational processing such as mitochondrial targeting. It appears that most new mutations occur in male sperm and are then passed on to a transmitting heterozygous female. Uncommonly, mild mutations are transmitted by asymptomatic males to their daughters, subsequently resulting in clinical disease of males in future generations. The causes for variable expressivity of these mutations are currently unknown but are likely to involve a combination of environmental and genetic modifiers.

摘要

鸟氨酸转氨甲酰酶(OTCase)缺乏症是最常见的遗传性尿素循环障碍,呈X连锁遗传。受影响的男性以及杂合子女性的临床表型严重程度不一,从新生儿高氨血症昏迷到无症状的成年人都有。鸟氨酸转氨甲酰酶是一种三聚体,每个全酶分子有三个活性位点,每个活性位点由一个多肽的结构域间区域和相邻多肽的极性结构域组成。OTC基因位于X染色体短臂上,在女性细胞中两个等位基因中的一个会发生失活。在受OTCase缺乏症影响的家族中已发现约140种突变,大多数有其自身的“私人”突变。约7%的患者可见一个或多个外显子的大片段缺失,约9%可见小缺失或插入,其余突变是单碱基替换。约15%的突变影响RNA剪接位点。反复出现的突变在CpG二核苷酸热点中均匀分布。一般来说,导致新生儿疾病的突变影响“埋藏”在酶内部的氨基酸残基,尤其是活性位点周围,而与迟发性和较轻表型相关的突变往往位于蛋白质表面。在前导肽序列中发现的突变很少,按比例比成熟酶序列中的少得多。只有少数突变已在细菌或哺乳动物细胞中表达以研究其有害机制。已表达突变的例子包括与迟发性疾病相关的R277W和R277Q,它们显著增加鸟氨酸的Km值,将最适pH值移向更碱性并降低纯化突变酶的热稳定性。R141Q(新生儿疾病)破坏活性位点,而纯化的R40H突变体具有正常的催化功能,这种突变可能影响翻译后加工,如线粒体靶向。似乎大多数新突变发生在男性精子中,然后传递给传递性杂合子女性。罕见的情况是,轻度突变由无症状男性传递给其女儿,随后导致后代男性出现临床疾病。这些突变可变表达的原因目前尚不清楚,但可能涉及环境和遗传修饰因子的组合。

相似文献

1
The biochemical and molecular spectrum of ornithine transcarbamylase deficiency.鸟氨酸转氨甲酰酶缺乏症的生化与分子谱
J Inherit Metab Dis. 1998;21 Suppl 1:40-58. doi: 10.1023/a:1005353407220.
2
Mutations and polymorphisms in the human ornithine transcarbamylase gene.人类鸟氨酸转氨甲酰酶基因中的突变和多态性。
Hum Mutat. 1993;2(3):174-8. doi: 10.1002/humu.1380020304.
3
The molecular basis of ornithine transcarbamylase deficiency: modelling the human enzyme and the effects of mutations.鸟氨酸转氨甲酰酶缺乏症的分子基础:人类酶的建模及突变的影响
J Med Genet. 1995 Sep;32(9):680-8. doi: 10.1136/jmg.32.9.680.
4
Identification of seven novel missense mutations, two splice-site mutations, two microdeletions and a polymorphic amino acid substitution in the gene for ornithine transcarbamylase (OTC) in patients with OTC deficiency.在鸟氨酸转氨甲酰酶(OTC)缺乏症患者中鉴定出该基因的七个新错义突变、两个剪接位点突变、两个微缺失和一个多态性氨基酸替代。
Hum Mutat. 2002 Feb;19(2):185-6. doi: 10.1002/humu.9011.
5
'Late onset' ornithine transcarbamylase deficiency: function of three purified recombinant mutant enzymes.
Hum Mol Genet. 1997 Jun;6(6):963-8. doi: 10.1093/hmg/6.6.963.
6
Mutations and polymorphisms in the human ornithine transcarbamylase gene.人类鸟氨酸转氨甲酰酶基因中的突变与多态性
Hum Mutat. 2002 Feb;19(2):93-107. doi: 10.1002/humu.10035.
7
Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonaemia.野生型人鸟氨酸转氨甲酰酶及一种导致“迟发性”高氨血症的复发性突变体的表达、纯化及动力学特性研究
Biochem J. 1997 Mar 1;322 ( Pt 2)(Pt 2):625-31. doi: 10.1042/bj3220625.
8
Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype.鸟氨酸转氨甲酰酶缺乏症的基因型谱:与临床和生化表型的相关性。
Am J Med Genet. 2000 Aug 14;93(4):313-9. doi: 10.1002/1096-8628(20000814)93:4<313::aid-ajmg11>3.0.co;2-m.
9
Identification of new mutations in the ornithine transcarbamylase (OTC) gene in Korean families.韩国家族中鸟氨酸转氨甲酰酶(OTC)基因新突变的鉴定。
J Inherit Metab Dis. 1996;19(1):31-42. doi: 10.1007/BF01799346.
10
Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene.人类鸟氨酸转氨甲酰酶(OTC)基因中的突变与多态性。
Hum Mutat. 2006 Jul;27(7):626-32. doi: 10.1002/humu.20339.

引用本文的文献

1
Biochemical Characterization of Disease-Associated Variants of Human Ornithine Transcarbamylase.人类鸟氨酸转氨甲酰酶疾病相关变体的生化特性
ACS Chem Biol. 2025 May 16;20(5):1059-1067. doi: 10.1021/acschembio.5c00043. Epub 2025 Mar 10.
2
Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency.一种新型条件性敲除小鼠模型的表征,用于评估在严重鸟氨酸转氨甲酰酶缺乏情况下mRNA疗法的疗效。
Mol Ther. 2025 Mar 5;33(3):1197-1212. doi: 10.1016/j.ymthe.2025.01.010. Epub 2025 Jan 10.
3
Revisiting the Roles of Catalytic Residues in Human Ornithine Transcarbamylase.

本文引用的文献

1
Substrate-induced conformational change in a trimeric ornithine transcarbamoylase.底物诱导的三聚体鸟氨酸转氨甲酰酶构象变化。
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9550-5. doi: 10.1073/pnas.94.18.9550.
2
'Late onset' ornithine transcarbamylase deficiency: function of three purified recombinant mutant enzymes.
Hum Mol Genet. 1997 Jun;6(6):963-8. doi: 10.1093/hmg/6.6.963.
3
Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonaemia.野生型人鸟氨酸转氨甲酰酶及一种导致“迟发性”高氨血症的复发性突变体的表达、纯化及动力学特性研究
重新审视人类鸟氨酸转氨甲酰酶中催化残基的作用。
Biochemistry. 2024 Jul 16;63(14):1858-1875. doi: 10.1021/acs.biochem.4c00206. Epub 2024 Jun 28.
4
Father-to-daughter transmission in late-onset OTC deficiency: an underestimated mechanism of inheritance of an X-linked disease.晚发性 OTC 缺乏症的父系传递:X 连锁疾病遗传的一种被低估的机制。
Orphanet J Rare Dis. 2024 Jan 2;19(1):3. doi: 10.1186/s13023-023-02997-8.
5
Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency.受鸟氨酸转氨甲酰酶缺乏症影响的单个家庭中的可变疾病表现和代谢管理。
Mol Genet Metab Rep. 2022 Jul 30;33(Suppl 1):100906. doi: 10.1016/j.ymgmr.2022.100906. eCollection 2022 Dec.
6
Pathogenic variants of ornithine transcarbamylase deficiency: Nation-wide study in Japan and literature review.鸟氨酸转氨甲酰酶缺乏症的致病变体:日本全国性研究及文献综述
Front Genet. 2022 Oct 11;13:952467. doi: 10.3389/fgene.2022.952467. eCollection 2022.
7
delivery of CRISPR-Cas9 therapeutics: Progress and challenges.CRISPR-Cas9疗法的递送:进展与挑战。
Acta Pharm Sin B. 2021 Aug;11(8):2150-2171. doi: 10.1016/j.apsb.2021.05.020. Epub 2021 May 26.
8
Primary hyperammonaemia: Current diagnostic and therapeutic strategies.原发性高血氨症:当前的诊断和治疗策略。
J Mother Child. 2020 Oct 2;24(2):32-38. doi: 10.34763/jmotherandchild.20202402si.2015.000006.
9
A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency.一种不依赖于突变的 CRISPR-Cas9 介导的基因靶向方法,用于治疗瓜氨酸转氨甲酰酶缺乏症的小鼠模型。
Sci Adv. 2020 Feb 12;6(7):eaax5701. doi: 10.1126/sciadv.aax5701. eCollection 2020 Feb.
10
Survival of a Male Infant with a Familial Xp11.4 Deletion Causing Ornithine Transcarbamylase Deficiency.一名患有因Xp11.4缺失导致鸟氨酸转氨甲酰酶缺乏症的男性婴儿的存活情况。
JIMD Rep. 2019;45:83-87. doi: 10.1007/8904_2018_145. Epub 2018 Nov 8.
Biochem J. 1997 Mar 1;322 ( Pt 2)(Pt 2):625-31. doi: 10.1042/bj3220625.
4
Relative frequency of mutations causing ornithine transcarbamylase deficiency in 78 families.78个家庭中导致鸟氨酸转氨甲酰酶缺乏症的突变相对频率。
Hum Genet. 1996 Mar;97(3):274-6. doi: 10.1007/BF02185751.
5
Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.患者选择可能会影响基因治疗的成功率。在小鼠和人类肝细胞中观察到鸟氨酸转氨甲酰酶的显性负效应。
J Clin Invest. 1996 Feb 1;97(3):826-32. doi: 10.1172/JCI118482.
6
The molecular basis of ornithine transcarbamylase deficiency: modelling the human enzyme and the effects of mutations.鸟氨酸转氨甲酰酶缺乏症的分子基础:人类酶的建模及突变的影响
J Med Genet. 1995 Sep;32(9):680-8. doi: 10.1136/jmg.32.9.680.
7
Seven new mutations in the human ornithine transcarbamylase gene.人类鸟氨酸转氨甲酰酶基因中的七个新突变。
Hum Mutat. 1994;4(1):57-60. doi: 10.1002/humu.1380040109.
8
Crystal structure of Pseudomonas aeruginosa catabolic ornithine transcarbamoylase at 3.0-A resolution: a different oligomeric organization in the transcarbamoylase family.铜绿假单胞菌分解代谢型鸟氨酸转氨甲酰酶3.0埃分辨率的晶体结构:转氨甲酰酶家族中不同的寡聚体结构
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10762-6. doi: 10.1073/pnas.92.23.10762.
9
Crystal and molecular structures of native and CTP-liganded aspartate carbamoyltransferase from Escherichia coli.来自大肠杆菌的天然及CTP配体结合的天冬氨酸氨甲酰基转移酶的晶体结构和分子结构
J Mol Biol. 1982 Sep 15;160(2):219-63. doi: 10.1016/0022-2836(82)90175-9.
10
RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression.不同类真核生物的RNA剪接连接:序列统计及其在基因表达中的功能意义
Nucleic Acids Res. 1987 Sep 11;15(17):7155-74. doi: 10.1093/nar/15.17.7155.